US20090311219A1 - Oncolytic Adenoviruses for Cancer Treatment - Google Patents
Oncolytic Adenoviruses for Cancer Treatment Download PDFInfo
- Publication number
- US20090311219A1 US20090311219A1 US12/184,881 US18488108A US2009311219A1 US 20090311219 A1 US20090311219 A1 US 20090311219A1 US 18488108 A US18488108 A US 18488108A US 2009311219 A1 US2009311219 A1 US 2009311219A1
- Authority
- US
- United States
- Prior art keywords
- promoter
- adenovirus
- sequence
- oncolytic
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 136
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 125
- 230000000174 oncolytic effect Effects 0.000 title claims abstract description 71
- 201000011510 cancer Diseases 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 82
- 230000014509 gene expression Effects 0.000 claims abstract description 71
- 230000001105 regulatory effect Effects 0.000 claims abstract description 52
- 230000014616 translation Effects 0.000 claims abstract description 49
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims description 104
- 102100024026 Transcription factor E2F1 Human genes 0.000 claims description 103
- 210000004881 tumor cell Anatomy 0.000 claims description 43
- 230000010076 replication Effects 0.000 claims description 25
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 15
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 238000001415 gene therapy Methods 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 210000000234 capsid Anatomy 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 241000598171 Human adenovirus sp. Species 0.000 claims description 7
- 239000012190 activator Substances 0.000 claims description 5
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 description 80
- 241000700605 Viruses Species 0.000 description 68
- 238000013519 translation Methods 0.000 description 28
- 230000003612 virological effect Effects 0.000 description 25
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- 108700005077 Viral Genes Proteins 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000003362 replicative effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 12
- 238000000316 virotherapy Methods 0.000 description 12
- 244000309459 oncolytic virus Species 0.000 description 11
- 230000033228 biological regulation Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 241001135569 Human adenovirus 5 Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 208000014829 head and neck neoplasm Diseases 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002101 lytic effect Effects 0.000 description 6
- 208000031448 Genomic Instability Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108010093502 E2F Transcription Factors Proteins 0.000 description 4
- 102000001388 E2F Transcription Factors Human genes 0.000 description 4
- 201000000582 Retinoblastoma Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 3
- 102000016897 CCCTC-Binding Factor Human genes 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010035601 Coxsackie and Adenovirus Receptor Like Membrane Protein Proteins 0.000 description 2
- 102000008198 Coxsackie and Adenovirus Receptor Like Membrane Protein Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 101710138750 Transcription factor E2F1 Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006951 hyperphosphorylation Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000984642 Cura Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 101150102539 E2F1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101100064560 Homo sapiens E2F1 gene Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101150096292 Ppme1 gene Proteins 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000001806 glycerol esters of wood rosin Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 102000050313 human E2F1 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
Definitions
- the field of the invention is related in general terms to the field of tumor biology.
- the invention refers to selective-replication adenoviruses in tumors, known as oncolytic adenoviruses, and their use to inhibit cancer.
- the tumor cell dies as a result of the cytopathic effect caused by the internal replication of the virus more than because of the effect of a therapeutic gene.
- Preferential replication in a tumor cell is called oncotropism and the lysis of the tumor is called oncolysis.
- Viruses that are replicated selectively in tumors are called oncolytic viruses.
- Cancer virotherapy significantly predates gene therapy.
- the first observations of tumor cure with viruses date from early in the last century. Already in 1912, De Pace observed tumor regressions after inoculating the rabies virus in cervical carcinomata 2 . Since then, many types of virus have been injected in tumors to treat them 3 .
- viruses that present a natural oncotropism for example the autonomous parvovirus, the vesicular-stomatitis virus 5 and the reovirus 6 .
- Other viruses can be manipulated genetically for selective replication in tumors.
- the herpes simplex virus has been made oncotropic on selecting the gene of ribonucleotide reductase, a dispensable enzyme activity in cells in active proliferation such as tumor cells 7 .
- the adenovirus in view of its low pathogenicity and high capacity to infect tumor cells, has been the virus used most in both virotherapy and gene therapy for cancer.
- Ad5 human adenovirus
- Ad5 infects epithelial cells, which during a natural infection are the cells of the bronchial epithelium. It enters the cells by means of interaction of the fiber, a viral protein that extends like an antenna from the twelve vertices of the capsid, with a cell protein involved in intercellular adhesion called Coxsackie-Adenovirus Receptor (CAR).
- CAR Coxsackie-Adenovirus Receptor
- E1A early 1A
- E2F is released to activate the transcription of other viral genes such as E2, E3 and E4 and cell genes that activate the cell cycle.
- E1B bonds with p53 to activate the cell cycle and prevent the apoptosis of the infected cell.
- E2 codifies for replication proteins of the virus, E3 for proteins that inhibit the antiviral immune response and E4 for proteins that transport viral RNA. The expression of these early genes leads to the replication of the viral DNA and once replicated, activates the promoter that regulates the expression of the late or structural genes that form the capsid.
- oncolytic adenoviruses Methods have been used to construct oncolytic adenoviruses: the selection of viral functions that are not necessary in tumor cells and the replacement of viral promoters with tumor-selective promoters 1 .
- the gene to be selected or regular gene belongs preferably to the E1 region, and in particular, affects E1a because it controls the expression of other viral genes.
- the protein E1b-55K has, for example, been eliminated. This protein inactivates p53 to induce in the infected cell the entry in phase S of the cell cycle and to prevent cell apoptosis.
- E1b-55K A mutated adenovirus in E1b-55K known as Onyx-015 has been used to treat tumors defective in p53 although with little clinical success owing to its low propagation capacity or oncolytic potency.
- Another mutation performed in the adenoviral genome to achieve selective replication in tumors affects the CR2 field of E1a.
- This E1a field mediates the bonding to proteins of the Retinoblastoma (Rb) family.
- pRb proteins block the transition of the Go/G1 phase to the S phase of the cell cycle, forming a complex transcription inhibitor along with E2F.
- E2F transcription factor of the pRb-E2F complex When E1a bonds with a pRb, the E2F transcription factor of the pRb-E2F complex is released and E2F acts as a transcriptional activator of the genes responsible for moving on to the S phase and viral genes such as E2.
- the release of E2F is thus a key step in the replication of the adenovirus.
- tumor cells the cell cycle is out of control because pRb is absent or inactivated by hyperphosphorylation and E2F is free. In these cells, the inactivation of pRb by E1a is now not necessary.
- an adenovirus with a mutation in E1a called Delta-24 that prevents its bonding with pRb can be propagated normally in cells with inactive pRb 9,10 .
- the E1a promoter has been replaced by various promoters such as the alpha-fetoprotein promoter, a prostatic-specific antigen (PSA), kallikrein, mucine 1 and osteocalcin 11-15 .
- PSA prostatic-specific antigen
- kallikrein kallikrein
- mucine 1 mucine 1
- osteocalcin 11-15 a major problem has been identified in the use of cell promoters in the viral context: the existence of viral sequences that interfere with the proper regulation of the promoter and reduce selectivity 16,17 . It has been attempted to correct this loss of selectivity by regulating other viral genes as well as E1a, such as E1b, E2 and E4 18,19 .
- the regulation of various viral genes can be done with a different promoter for each viral gene, for example the E2F1 promoter for E1a and the telomerase promoter for E4.
- the two promoters must be expressed at high levels to allow viral replication such that oncolytic potency can remain reduced in many tumor cells 20 .
- two viral genes can be regular with the same promoter, for example in the oncolytic adenovirus Onyx 411, in which E1a and E4 are regulated by the E2F1 promoter 21 .
- E1a and E4 are regulated by the E2F1 promoter 21 .
- E2F1 promoter 2021,29,30 A particularly interesting promoter used in the design of oncolytic adenoviruses is the E2F1 promoter 20,21,29,30 .
- This promoter presents two E2F bonding sites.
- the family of E2F transcription factors regulates the transcription of genes that allow entry to the S phase of the cell cycle. These factors serve as activators when they are released and as repressors when they bond with the pRb retinoblastoma protein 31 .
- the bonding of pRb to E2F is regulated by phosphorylation of pRb such that the phosphorylation of pRb prevents its bonding with E2F.
- Tumors present alterations in the signal-translation routes that result in the hyperphosphorylation of pRb and an increase in free E2F.
- genes are expressed that respond to E2F such as the E2F1 gene.
- pRb is not phosphorylated and remains bonded to E2F, forming a complex that acts as a transcriptional repressor.
- oncolytic adenoviruses however, the simple regulation of E1a with the E2F1 promoter results in a low level of selective replication in tumors, of the order of 10 times 20 .
- the regulation of other viral genes in addition to E1a is a possible solution to this low selectivity, but presents the problems described in the paragraph above.
- OAS403 is an oncolytic adenovirus with E1a regulated with the promoter of E2F1 and E4 regulated with the promoter of telomerase, which furthermore includes a polyadenylation signal to eliminate transcription from the ITR (inverted terminal repetition) and in which the packaging signal has been relocated to the extreme right of the genome to reduce interference with the E1a promoter 20 .
- ITR inverted terminal repetition
- packaging signal has been relocated to the extreme right of the genome to reduce interference with the E1a promoter 20 .
- the packaging signal and sequences adjacent to E4 change position in the genome 22 . It has moreover been described that even minor modifications of the E4 region cause genomic instability, and so strategies based on modification of the E4 region have been abandoned 22 .
- E2F1 promoter Another problem found with the E2F1 promoter apart from its selectivity is the lack of potency.
- an oncolytic adenovirus with E1a regulated by the E2F1 promoter loses its lytic capacity with regard to the salvage adenovirus as shown by Ryan et al. 20 and in the examples presented in this invention.
- This invention describes the use of appropriate DNA sequences to achieve the correct functioning of a genome promoter of an oncolytic adenovirus. With these sequences, an oncolytic adenovirus is designed that presents greater selectivity and anti-tumor potency.
- the use of the elements described in this invention allows the attainment of a high tumor selectivity and oncolytic capacity using only a tumor-specific promoter.
- the use of a single promoter reduces the problems of genomic instability associated with the repetition of the same promoter in the adenoviral genome.
- the regulation of only E1a avoiding the regulation of other viral genes, allows the correct temporal regulation of adenoviral genes and prevents the genomic instability associated with modification of the E4 region.
- This invention refers to an oncolytic adenovirus for cancer treatment that contains a human DNA sequence isolating a promoter that confers selective expression on an adenoviral gene.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- adenovirus contains a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter that confers tumor selectivity.
- this sequence is the Kozak sequence.
- Another object of the invention is an oncolytic adenovirus for cancer treatment that contains a human DNA sequence isolating a promoter of selective expression that regulates an adenoviral gene and a sequence that optimizes the protein translation of the same adenoviral gene.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- Another object of this invention is an adenovirus that contains a human DNA sequence isolating a promoter of selective expression that regulates an adenoviral gene and a sequence that optimizes the protein translation of the same adenoviral gene and that also presents mutations in one or more genes of the E1a, E1b and E4 group to achieve selective replication in tumors.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- Yet another object of this invention is an oncolytic adenovirus that contains a human DNA sequence isolating a promoter of selective expression that regulates an adenoviral gene and a sequence that optimizes the protein translation of the same adenoviral gene and modifications in its capsid to increase its infectivity or to direct it to a receptor present in a tumor cell.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- Yet another object of this invention is an oncolytic adenovirus that contains a human DNA sequence isolating a promoter of selective expression that regulates an adenoviral gene and a sequence that optimizes the protein translation of the same adenoviral gene and that said adenovirus, in turn, contains other genes commonly used in the field of cancer gene therapy as prodrug activators, tumor suppressors or immunostimulators.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- Yet another object of this invention is an oncolytic adenovirus that contains a human DNA sequence isolating a promoter of selective expression that regulates an adenoviral gene and a sequence that optimizes the protein translation of the same adenoviral gene
- the adenovirus is a human adenovirus derived from a serotype between 1 and 50.
- the adenovirus is a human adenovirus serotype 5.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- Yet another object of this invention is an oncolytic adenovirus that contains a human DNA sequence isolating the promoter of the modified human E2F1 gene by the addition of sites for bonding to E2F to regulate the expression of an adenoviral gene and a sequence that optimizes the protein translation of the same gene.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- Another object of this invention is a pharmaceutical composition that includes an effective quantity of an oncolytic adenovirus that contains a human DNA sequence isolating a promoter of selective expression that regulates an adenoviral gene and a sequence that optimizes the protein translation of the same adenoviral gene and one or more pharmaceutically acceptable carriers and excipients.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- Another object of this invention is the use of an oncolytic adenovirus that contains a human DNA sequence isolating a promoter of selective expression that regulates an adenoviral gene and a sequence that optimizes the protein translation of the same adenoviral gene for the preparation of a drug for the treatment or prevention of cancer or a premalignant condition thereof.
- the human DNA sequence is a sequence derived from the locus of myotonic dystrophy.
- the adenovirus of this invention may optionally be combined with other methods of cancer treatment such as chemotherapy or radiotherapy.
- This invention describes an oncolytic adenovirus that contains a human DNA sequence, in particular a sequence derived from the locus of myotonic dystrophy, as a sequence isolating a promoter of selective expression that regulates an adenoviral gene and, in turn, contains a sequence that optimizes the protein translation of the same adenoviral gene, as well as the use of said oncolytic adenovirus for the treatment or prevention of cancer or a premalignant condition thereof.
- Previously, the use of isolating sequences derived from B-globin of chickens in adenoviral vectors has been described 26,27 .
- the isolators described previously are not of human origin and have not been used in a context of oncolytic adenoviruses.
- the locus of myotonic dystrophy is located in the human chromosome 13 in the position 19q13.3. This locus contains two bonding sites for the CTCF protein and a variable number according to each individual of CTG repetitions that jointly function as a potent isolator of the effect of enhancers or activators on promoters 32 .
- its activity had never been analyzed in a viral genome. Its activity in a viral genome is not obvious, as its activity has been demonstrated only in the context of a cell chromosome in which the associated histones can play a role in its functioning.
- Its human origin offers a superior alternative to the use of the HS4 sequence of chickens as the transfer of sequences of non-human origin can have biosafety implications.
- this invention describes the use of an optimized sequence for protein translation to increase the levels produced of the adenoviral protein regulated below the tumor-specific promoter.
- the regulation of the expression of a viral gene with a tumor-selective promoter presents the disadvantage that the level of expression is usually lower than the level of expression observed in Ad5. This lower expression results in lower replicative potency of the oncolytic adenovirus. Insertion of the Kozak sequence at the beginning of translation of the gene regulated by the selective promoter is capable of restoring the levels of expression of the gene regulated.
- This invention also describes the strategy of increasing the number of binding sites at E2F in the sequence of the human promoter E2F1 to better control the expression of E1a in an oncolytic adenovirus.
- This increase in binding sites at E2F produces greater expression of E1a in tumor cells and reduced expression of E1a in normal cells, resulting in an increase in tumor selectivity of adenoviral replication.
- the invention is directed towards the need to find better treatments for cancer, including, but not limited to, cancer of the pancreas, colon and lung.
- Cancer treatment with the oncolytic adenovirus that contains the human DNA sequence and the sequence that optimizes protein translation can be performed by direct injection inside the tumor or by systemic intravenous injection in patients suffering from cancer using standard methods in the field of gene therapy and virotherapy with adenoviruses.
- FIG. 1 Structure of adenovirus expounded in this invention.
- the arrows indicate the modifications most representative of each virus regarding parental versions.
- Adwt is the wild virus with no modification. It shows inverted terminal regions (ITR) for its replication and a packaging signal ( ⁇ ) together with ITR on the left.
- ITR inverted terminal regions
- ⁇ packaging signal
- the virus AdwtRGD coincides with Adwt but also contains the tripeptide sequence RGD (Arginine-Glycine-Aspartic Acid) in the sequence of the viral fiber. This sequence serves to bind 5 integrins that are overexpressed in the membrane of tumor cells. This virus is used as a positive control of replication.
- the virus Ad- ⁇ 24RGD is similar to AdwtRGD but has a deletion of 24 nucleotides, corresponding to 8 amino acids, in the binding site of E1a to pRB. Said deletion prevents the separation of complex pRB-E2F present in quiescent normal cells so that said virus is preferentially replicated in cells in division or tumor cells. This virus is used to compare the level of selectivity of the viruses described in this invention.
- the Ad-TLRGD virus is a virus similar to AdwtRGD but with the E1 region replaced by luciferase genes and green fluorescence protein (GFP) genes. This virus because it lacks the E1 region cannot be replicated and is used as a negative control.
- the ICOVIR viruses are derived from Ad- ⁇ 24RGD by the substitution of the E1a promoter by a selective activation promoter in tumors, promoter E2F1.
- ICOVIR1 is similar to Ad- ⁇ 24RGD but contains said substitution.
- This virus is used as a control of E1A expression, controlled by promoter E2F1 in the absence of insulating sequences of the promoter.
- ICOVIR2 is similar to ICOVIR1 but contains a sequence of the myotonic dystrophy locus at promoter E2F1.
- ICOVIR5 also contains the Kozak sequence in the beginning of translation of E1a in order to optimize its translation and thus increase the levels of expression of E1a in tumor cells.
- ICOVIR7 also has two additional binding sites to E2F in the E2F1 promoter.
- the ICOVIR2, 5 and 7 viruses serve to demonstrate the object of this invention: the best gene regulation when the DM insulating sequence is used.
- FIG. 2 Diagram of the functioning of oncolytic adenoviruses containing the DM sequence of the myotonic dystrophy insulating locus at promoter E2F1 that regulates E1a.
- the oncolytic viruses ICOVIR2, 5 and 7 contain promoter E2F1 insulated with the DM sequence.
- the first codon of the E1a sequence is preceded by the Kozak sequence (CCACC) to optimize protein translation.
- CCACC Kozak sequence
- the promoter of E2F1 is modified by the insertion of additional binding sites to E2F to increase its potency and selectivity.
- complex pRB E2F acts as a repressor of the promoter of E2F1 through the action of histone deacetylases (HDAC) and E1a is not expressed.
- HDAC histone deacetylases
- pRB is hyperphosphorylated or absent and E2F is free. In this manner it acts as a transcriptional activator of E1a.
- the Kozak sequence preceding E1a allows a correct level of expression of E1a.
- the insulating DM avoids the interference of the ITR and adenoviral packaging signal in the modified E2F1 promoter.
- FIG. 3 demonstration of the effect on the expression of E1a resulting from the insertion of a DM insulating sequence in front of the E2F1 promoter.
- Endothelial cells from human umbilical cord (HUVEC), human fibroblasts and human hepatocytes are used as controls of non-tumor cells.
- the cell lines NP-9 (adenocarcinoma of the pancreas), A-549 (adenocarcinoma of the lung), FaDu (head and neck tumors), SCC25 (head and neck tumors), SKMel-28 (melanoma) and 1.36.1.5 (melanoma) are used as a model of the human tumor cell.
- Adwt and AdwtRGD positive controls of non-selective expression of E1a
- Ad- ⁇ 24RGD non-selective expression of E1a-D24
- ICOVIR1 E1a controlled by promoter E2F1
- ICOVIR2 E1a controlled by promoter E2F1 insulated with the DM sequence, object of this invention
- O represents a cellular extract of uninfected cells.
- virus Ad-TLRGD which has region E1 replaced by luciferase genes and green fluorescence protein (GFP) genes. This negative control shows no expression of E1a.
- ICOVIR1 and ICOVIR2 tumor cells are capable of expressing E1a, but in FaDu, SCC25 and SKMel-28, the expression of E1a in cells infected with ICOVIR1 or ICOVIR2 is lower than that obtained with the adenovirus where E1a is not regulated by E2F1 (virus Adwt, AdwtRGD and Ad- ⁇ 24RGD).
- E2F1 virus Adwt, AdwtRGD and Ad- ⁇ 24RGD.
- the promoter of E2F1 insulated or not with DM, does not have the power required to allow a level of expression of E1a in tumor cells comparable to wild adenovirus.
- this invention solves this problem with insertion of the Kozak sequence in E1a (in ICOVIR5) and modification of the promoter E2F1 (in ICOVIR7).
- FIG. 4 The DM sequence allows for an increase in antitumor selectivity of an oncolytic adenovirus with E1a regulated with the promoter of E2F1.
- the amount of virus in the cell extract was determined by infection of a monolayer of HEK293 cells and subsequent staining with the monoclonal antibody 2Hx-2 (ATCC) that recognizes the adenoviral hexon and a mouse anti-IgG secondary antibody, Alexa 488 (Molecular Probes, Eugene, Oreg.).
- the monolayer was observed under fluorescence microscope and every fluorescent cell was quantified as a transduction unit (TU). Thus, the number of units per milliliter of viral extract was determined. The bars show said number of units of transduction per milliliter of viral extract.
- ICOVIR2 The presence of the DM insulating sequence in ICOVIR2 results in a lower viral replication in normal fibroblasts and HUVEC compared with ICOVIR1 which has the non-insulated promoter E2F1.
- NP-9 adenocarcinoma of the pancreas
- A-549 adenocarcinoma of the lung
- FaDu head and neck tumors
- SCC25 head and neck tumors
- SKMel-28 melanoma
- 1.36.1.5 (melanoma).
- this invention describes the method to preserve the selectivity provided by promoter E2F1 insulated with DM by increasing the replicative capacity via the insertion of the Kozak sequence in E1a and modification of promoter E2F1.
- FIG. 5 Effect of inserting the Kozak sequence to increase the power of the promoter insulated with DM.
- Human fibroblasts were infected with AdwtRGD (positive control of infectivity increased by the RGD sequence and non-selective expression of E1a) and oncolytic viruses Ad- ⁇ 24RGD (non-selective expression of E1a- ⁇ A24), and ICOVIR5 (E1a preceded by the Kozak sequence and controlled by promoter E2F1 insulated with the DM sequence). After 24 hours the cells were read and E1a was detected by Western blot. The band corresponding to E1a in fibroblasts infected with ICOVIR5 is less intense than that for fibroblasts infected with the control virus.
- FIG. 6 In vitro oncolytic effectiveness of adenoviruses containing E1a regulated with the promoter of E2F1 insulated with the DM sequence and the Kozak sequence to optimize translation of E1a.
- Cells from the melanoma tumor line SKMel28 or head and neck tumor FaDu were cultured in wells from a plate of 96 wells (3000 cells per well) and were infected with increasing concentrations of AdwtRGD (positive control of infectivity increased by the RGD sequence and non-selective expression of E1a), ICOVIR2 (E1a controlled by the promoter E2F1 insulated with the DM sequence), or ICOVIR5 (E1a preceded by the Kozak sequence and controlled by the promoter E2F1 insulated with the DM sequence).
- AdwtRGD positive control of infectivity increased by the RGD sequence and non-selective expression of E1a
- ICOVIR2 E1a controlled by the promoter E2F1 insulated with the DM sequence
- ICOVIR5 E1a preceded by the Kozak sequence and controlled by the promoter E2F1 insulated with the DM sequence.
- the X-axis shows the concentration of viral particles
- CPE cytopathic effect
- FIG. 7 Effect of modification of E2F1 promoter to increase its power when it is insulated with the DM sequence.
- Cells of the melanoma tumor line 1.36.1.5. were infected with Ad-TLRGD (non-replicative negative control of virus for lack of E1a), AdwtRGD (positive control of infectivity increased by the RGD sequence and non-selective expression of E1a), and oncolytic viruses ICOVIR2 (E1a controlled by the E2F1 promoter insulated with the DM sequence), ICOVIR5 (E1a preceded by the Kozak sequence and controlled by the promoter E2F1 insulated with the DM sequence) and ICOVIR7 (E1a preceded by the Kozak sequence and controlled by a promoter E2F1 modified by two additional binding sites to E2F and insulated with the DM sequence).
- Ad-TLRGD non-replicative negative control of virus for lack of E1a
- AdwtRGD positive control of infectivity increased by the RGD sequence and non-selective expression of E1a
- oncolytic viruses ICOVIR2 (
- the amount of virus in the cell extract was determined by infection of a monolayer of HEK293 cells and subsequent staining with the monoclonal antibody 2Hx-2 (ATCC) that recognizes the adenoviral hexon and a mouse anti-IgG secondary antibody, Alexa 488 (Molecular Probes, Eugene, Oreg.). The monolayer was observed under fluorescence microscope and every fluorescent cell was quantified as a transduction unit (TU).
- ATCC monoclonal antibody 2Hx-2
- Alexa 488 Molecular Probes, Eugene, Oreg.
- the number of transduction units per milliliter (TU/ml) of viral extract was determined.
- AdwtRGD is used, in which E1a is not regulated.
- ICOVIR7 is capable of propagating with the same power as the control AdwtRGD.
- FIG. 8 An adenovirus containing E1a regulated with promoter E2F1 insulated with the DM sequence and Kozak sequence at the beginning of translation of E1a can be used to treat tumors.
- the top of the figure shows an experiment in vivo with athymic mice of the BALB/c strain containing NP9 tumors.
- the tumors were injected with PBS ( ⁇ ) or 109 viral particles of ICOVIR-2 ( ⁇ ) or AdwtRGD ( ⁇ ).
- the graph shows the evolution of tumor volume.
- ICOVIR2 can inhibit tumor growth.
- FIG. 9 Demonstration in vivo of the reduction of toxicity after intravenous injection of adenovirus containing regulated E1a with the promoter of E2F1 insulated with the DM sequence and the Kozak sequence to optimize translation of E1a.
- the toxicity in vivo of an adenovirus containing the Kozak sequence in E1a and a promoter E2F1 insulated by DM was compared with that of the wild virus Adwt and the oncolytic virus Ad- ⁇ 24RGD expressing E1a under its natural promoter.
- the viruses were administered intravenously at different doses (10 10 , 5 ⁇ 10 10 and 10 11 ) in immunocompetent Balb/c mice. For 3 days post-injection, parameters associated with toxicity were evaluated. A shows the number of deaths with respect to the number of animals treated. This mortality includes animals sacrificed for having a weight loss equal to or greater than 20%.
- B represents the percentage variation in body weight for each group of animals treated with the control vehicle (PBS) or different viruses at the doses indicated.
- C shows the international units (IU) of serum transaminases aspartate aminotransferase (AST) and alanine-aminotransferase (ALT) per liter of blood plasma detected after the intravenous injection of the control vehicle or the viruses indicated at the doses indicated.
- D shows the number of platelets per milliliter of blood detected after intravenous injection of the control vehicle or the viruses indicated at the doses indicated. For each of these parameters the toxicity associated with the administration of ICOVIR 5 is very low even at the highest dose.
- FIG. 10 Demonstration in vivo of reduction in the expression of E1a in non-tumor tissue and toxicity after intravenous injection of adenovirus containing E1a regulated with the promoter of E2F1 insulated with the DM sequence and the Kozak sequence to optimize the translation of E1a.
- This invention describes the use in cancer treatment of adenoviruses that contain E1a regulated with the E2 ⁇ l promoter isolated with the MD sequence, the Kozak sequence to optimize E1a translation and the addition of sites for bonding to E2F in the E2F1 promoter.
- the treatment is based on the selective replication of these viruses in tumors that have an altered retinoblastoma route.
- the retinoblastoma route is the set of protein interactions that occur from the cell membrane up to the nucleus to regulate the level of phosphorylation of the protein of retinoblastoma pRb. Cancer is characterized by an alteration of this route such that the pRb protein is hyperphosphorylated or lost. This pRb alteration causes a loss of pRb bonding to the E2F transcription factor and an increase in free E2F in the nucleus of the tumor cells. This transcription factor bonds to the promoters with specific E2F bonding sites, as an E2F1 promoter, to increase its expression.
- the selective-replication mechanism in tumors of adenoviruses containing E1a regulated with the E2F1 promoter isolated with the MD sequence, the Kozak sequence at the start of E1a translation and the addition of sites for bonding to E2F in the E2F1 promoter is based on the idea that the presence of free E2F in the tumors activates the expression of the E2F1 promoter in this virus and is indicated in FIG. 2 of this invention.
- the presence of the MD sequence enables correct activation of the promoter.
- the presence of the Kozak sequence enables synthesis of a quantity of E1a sufficient for maintaining the appropriate replicative and lytic capacity of the oncolytic virus.
- the presence of additional sites for bonding to E2F in the E2 ⁇ l promoter enables an increase in the level of expression of E1a to maintain the appropriate replicative and lytic capacity of the oncolytic virus.
- the DM insulating human sequence derived from the locus of myotonic dystrophy is represented by SEQ. ID 1 (from position 368 to 1096 of sequence 1).
- the DM sequence is characterized in that it contains two binding sites to factor CTCF and a variable number of repetitions of sequence CGT which function together as a powerful insulator against transcriptional interference 32 .
- the DM sequence acts to insulate the effect of enhancers, located in the sequence of adenovirus packaging next to the promoter of E1a.
- the promoter of E1a is replaced by a selective promoter of tumors such as, for example, the promoter E2F1 and, to insulate this promoter from the enhancers present in the sequence of adenoviral packaging, the DM sequence is inserted between said sequence of packaging and promoter E2F1.
- the sequence of the promoter of E2F1 is shown in SEQ. ID 1 (from position 1283 until position 1564 of sequence 1). This promoter is characterized by having two binding sites to E2F organized in imperfect palindromes and four binding sites to Sp1 34 .
- the sequence of promoter E2F is modified by the insertion of binding sites to E2F in addition to those that already exist in the wild human promoter (from position 1321 until position 1447 of SEQ.
- adenoviral genome 41 There are several ways to manipulate the adenoviral genome.
- the methods of construction of genetically modified adenoviruses are well established in the field of gene therapy and virotherapy with adenovirus 36-41 .
- the most commonly used method is based on first building the genetic modification desired into a plasmid that contains the adenoviral region to be modified, and then performing a homologous recombination in bacteria with a plasmid that contains the first of the viral genome 41 . This process can be as follows:
- adenoviruses with the expression of a viral gene regulated by the selective promoter isolated with the MD sequence and potentiated with the Kozak sequence can contain modifications of their capsid to increase their inefficacy or be directed to receptors present in the tumor cell.
- the proteins of the adenoviral capsid have been genetically modified to include ligands that increase inefficacy or direct the virus to a receptor in the tumor cell 47-53 . Directing the adenovirus to the tumor can also be achieved with bifunctional ligands that bond to the virus on one side and to the tumor receptor on the other 53-56 .
- the capsid can be covered with polymers such as polyethylene glycol 57-60 .
- polymers such as polyethylene glycol 57-60 .
- Another feature of this invention is adenoviruses that contain E1a regulated with the E2F1 promoter isolated with the MD sequence, the Kozak sequence at the start of E1a translation and the addition of sites for bonding to E2F in the E2F1 promoter, but which are derived from other serotypes of adenoviruses other than Ad5.
- Another feature of this invention refers to adenoviruses that contain E1a regulated with the E2F1 promoter isolated with the MD sequence, the Kozak sequence at the start of E1a translation and the addition of sites for bonding to E2F in the E2F1 promoter and that, in turn, contain other genes for increasing their cytotoxicity to tumor cells such as the gene of thymidine kinase, cytosine deaminase, proapoptotic genes, immunostimulators or tumor suppressors.
- the adenoviruses described in this invention are propagated following standard methods in the fields of adenovirology and adenoviral vectors 36,37 .
- the preferred propagation method is by infection of a cell line permitting the replication of adenoviruses that contain E1a regulated with the E2F1 promoter isolated with the MD sequence, the Kozak sequence at the start of E1a translation and the addition of sites for bonding to E2F in the E2F1 promoter.
- the line of pulmonary adenocarcinoma A549 is an example of this line. Propagation is performed, for example, as follows: The A549 cells are grown on plastic plates for cell cultivation and infected using 50 viral particles per cell.
- the cells are collected and stored in tubes. After centrifugation at 1,000 rpm for 5 minutes, the cell precipitate is frozen and thawed three times to break the cells. The resulting cell extract is centrifuged at 1,000 rpm for 5 minutes and the supernatant with viruses is loaded above a gradient of caesium chloride and centrifuged for 1 hour at 35,000 rpm. The virus band in the gradient is reloaded above another gradient of caesium chloride and centrifuged for 16 hours at 35,000 rpm. The virus band is collected and dialyzed with PBS-10% glycerol. The dialyzed virus is aliquoted and stored at ⁇ 80° C. The number of particles and plate-forming units is quantified following standard protocols 39 .
- a saline phosphate buffer with glycerol at 10% is a standard formulation for storing adenoviruses.
- new formulations have been described that improve the stability of the virus 61,62 .
- This invention describes the use of adenoviruses that contain E1a regulated with the E2F1 promoter isolated with the MD sequence, the Kozak sequence at the start of E1a translation and the addition of sites for bonding to E2F in the E2F1 promoter for the treatment of cancer.
- the treatment is based on the selective replication of these viruses in cells with an active RB route.
- the protocols for using the viruses described in this invention in the treatment of cancer follow the same procedures as those used in the fields of virotherapy with adenoviruses and gene therapy with adenoviruses.
- adenoviruses with selective-replication methods other than that proposed in this invention have been used to treat cancer 9,37,63-68 .
- the purified adenovirus in any of the forms described above is added to the culture medium for the infection of tumoral cells.
- the adenovirus can be administered locoregionally by injection in the tumor or in a body cavity where the tumor is located, or even systematically by injection into the bloodstream.
- adenovirus replications can be administered loco-regionally by injection in the tumor or in a body cavity where the tumor is located, or systemically by injection in the bloodstream.
- the treatment of tumors with the adenoviruses described that are the subject of this invention can be combined with other methods of treatment such as chemotherapy or radiotherapy.
- An adenovirus was constructed with E1a regulated with the E2F1 promoter isolated with the MD sequence as follows: To generate ICOVIR-1 (Ad-E2F- ⁇ 24RGD), the human E2F1 promoter was obtained by PCR of mononuclear cells of human peripheral blood using oligonucleotides stretching from the pair of bases ⁇ 218 to +51 of the E2F-1 promoter (position +1 indicates the start of transcription). The oligonucleotides contained KpnI and HindIII restriction targets for cloning in the plasmid pGL3 (Promega, Southampton, UK). The resulting plasmid was called pGL3-E2F.
- pE2F- ⁇ 24 by recombination with a plasmid containing the 5,766 pairs of base from the extreme left of the adenoviral genome except nucleotides (nt) 122 and 129 of E1a (derived from pXC1- ⁇ 24 with a HindIII site between nt 348 and nt 522 of the Ad5 genome 9 ).
- pE2F- ⁇ 24 was recombined with pShuttle 41 to obtain pShuttle-E2F- ⁇ 24.
- This plasmid was linearized with Pme1 and recombined with pVK503 (which contains the Ad5 sequence with the fiber modified with RDG 69 ) to generate the plasmid pAd-E2F- ⁇ 24RGD or pICOVIR-1.
- the combination of the E2F1 promoter and other modifications described in this invention with the E1a mutation called ⁇ 24 and the insertion of the peptide RGD in the fiber was done to demonstrate that the modifications presented in this invention increases the oncolytic potency and selectivity of a virus known as selective towards Rb and powerful in the field of oncolysis (adenovirus Ad- ⁇ 24RGD 70 ).
- the mutation ⁇ 24 and the insertion of peptide RGD are modifications described above in the field of virotherapy of cancer. In particular, they have been described together in reference 70 of this invention.
- This reference describes the use of the RGD peptide.
- This peptide is a tripeptide formed by the amino acids Arginine, Glycine and Aspartic Acid, which are bound to the integrins. Since the integrins are over-expressed in tumor cells, tripeptide RGD serves to increase the infectivity of the virus in tumor cells and is used for this purpose.
- the virus ICOVIR1 was generated by digestion with PacI of this plasmid and transfection in HEK293 cells.
- ICOVIR-2 Ad-DM-E2F- ⁇ 24RGD
- the DM-1 insulating sequence was obtained from PCR of human peripheral mononuclear blood cells using oligonucleotides that amplify from nt 13006 to nt 13474 of locus DM1 (sequence published in GenBank with number L08835). Oligonucleotides of the PCR were designed to incorporate flanking sites Xho I. DM-1 was subcloned in Xho1 of pShuttle-E2F- ⁇ 24 described above to obtain pShuttle-DM-E2F- ⁇ 24.
- the correct orientation of the DM1 fragment was verified by restriction with BamH1, Hind111, Xho1 and Sma1.
- pShuttle-DM-E2F- ⁇ 24 is recombined with pVK503 to generate plCOVIR2.
- the virus ICOVIR2 was generated by digestion with PacI from this plasmid and transfection in HEK293 cells.
- ICOVIR1 and ICOVIR2 spread in the A549 line and were purified by methods described in gene therapy and virotherapy 36 .
- the correct structure of the genomes of ICOVIR-1 and ICOVIR-2 was verified by restriction with Kpn1 and HinIII, respectively.
- DM-1 region, promoter E2F, mutation E1A- ⁇ 24 and the region of the fiber containing RGD were sequenced.
- the oligonucleotides used for these sequencings are: DM1-Up (5′-GGGCAGATGGAGGGCCTTTTATTC-3′), E2F-Up (5′-GTGTTACTCATAGCGCGTAA-3′), ⁇ 24-down (5′-CCTCCGGTGATAATGACAAG-3′) and FiberUp (5′-CAAACGCTGTTGGATTTATG-3′). The sequences obtained are shown in SEQ. ID 1.
- the cells were lysed in a lysis buffer (400 mM NaCl, 1 mM EDTA, 5 mM NaF, 10% glycerol, 1 mM sodium orthovanadate, 0.5% Nonidet P-40, 100 ⁇ g/ml phenylmethylsulfonyl fluoride, 1 ⁇ g/ml leupeptin and 10 ⁇ g/ml aproptinin in 10 mM Tris-HCl (pH 7.4) for 1 hour at 4° C.
- a lysis buffer 400 mM NaCl, 1 mM EDTA, 5 mM NaF, 10% glycerol, 1 mM sodium orthovanadate, 0.5% Nonidet P-40, 100 ⁇ g/ml phenylmethylsulfonyl fluoride, 1 ⁇ g/ml leupeptin and 10 ⁇ g/ml aproptinin in 10 mM Tris-HCl (pH 7.4) for 1 hour at 4°
- the lysate was centrifuged at 14,000 rpm, and the supernatant with proteins was separated by electrophoresis in 10% SDS-PAGE (25 ⁇ g/track, determined by Bradford, BioRad, CA, USA) and transferred to nitrocellulose (Schleicher and Schuell, Dassel, Germany).
- the membrane was blocked with 5% skimmed milk, 0.05% Tween 20 and 0.9% NaCl in 50 mM Tris (pH 7.5), and incubated for 16 hours at 4° C. with a polyclonal antibody anti-adenovirus-2-E1a (clone 13 S-5, Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA).
- E1a was detected with a secondary anti-rabbit IgG antibody (DAKO A/S) joined with peroxydase and Amersham's Enhanced Chemiluminescence protocol (Amersham, Arlington Heights, Ill., USA). The result is shown in FIG. 3 of this invention. It is shown that the presence of the E2F1 promoter (ICOVIR1) is capable of reducing the expression of E1a in normal cells. But the MD sequence confers greater control of the expression of E1a by the E2F promoter (ICOVIR2).
- both ICOVIR1 and ICOVIR2 are capable of expressing E1a, but it is important to note that in some tumor lines such as FaDu, SCC25 and SKMel-28, the expression of E1a is less than that obtained with the salvage adenovirus and the oncolytic AdD24RGD in which E1a is not regulated by E2F1. This indicates that the E2F1 promoter, whether isolated or not with MD, does not have the necessary potency to enable a level of expression of E1a in tumor cells comparable to the salvage adenovirus.
- the cells were infected with ICOVIR1 and ICOVIR2 as described in the previous paragraph. Five days after infection, the cells and their culture media were collected and submitted to three cycles of freezing-thawing to release the virus. The quantity of the virus in the cell extract was determined by infection in HEK293 and anti-hexon staining using the monoclonal antibody 2Hx-2 (ATCC) and a secondary antibody, Alexa 488 anti-IgG of a rat (Molecular Probes, Eugene, Oreg.). The result is shown in FIG. 4 .
- ICOVIR1 The presence of the E2F1 promoter in ICOVIR1 reduces viral replication in normal cells (fibroblasts and HUVEC). However, the isolating sequence in ICOVIR2 results in lower viral replication. In certain tumor-cell lines such as A549, ICOVIR1 and ICOVIR2 show a level of replication similar to the salvage adenovirus Adwt, but in the majority of tumor lines, its replicative capacity is less than that of Adwt.
- the Kozak Sequence Enables an Increase in the Expression of E1a an Oncolytic Adenovirus in which the Expression of E1a is Regulated with the E2F1 Promoter Isolated with the MD Sequence
- An oncolytic adenovirus was constructed with E1a regulated with the E2F1 promoter isolated with the MD sequence and with the Kozak sequence to increase its translation.
- E1a a fragment of DNA containing the MD sequence, the E2F1 promoter and E1a was isolated from the pShuttle-MD-E2F-D24 described in example 1 by restriction with Kpn1 and subcloned in pGEM3Z (Promega), obtaining the plasmid pGEM-E2F-d24.
- This plasmid was used to replace the start of E1a translation using oligonucleotides with the Kozak sequence obtaining pGEM-E24-KD24.
- the Kpn1 fragment thus modified was recloned in Kpn1 from pShuttle-DM-E2F-D24 to obtain pShuttle-DM-E2F-KD24. Finally, pShuttle-DM-E2F-KD24 was recombined with pVK503 to obtain pICOVIR5.
- the virus ICOVIR5 was generated by digestion with PacI of this plasmid and transfection to HEK293 cells. ICOVIR5 was propagated in the A549 line and purified by methods described in gene therapy and virotherapy 36 . Its structure is presented in FIG. 1 of this invention. The correct sequence of the promoter and E1a was checked by restriction and sequencing. The sequence obtained is shown in SEQ.
- E1a is expressed conditionally in tumor cells when its expression is regulated with the E2F1 promoter isolated with the MD sequence and in addition, its translation is optimized with the Kozak sequence
- the expression of E1a was analyzed as described in example 1. In this case, it was included in oncolytic adenovirus ICOVIR5, which is distinguished from ICOVIR2 by the fact that it contains the Kozak sequence in the start of E1a translation. The results are shown in FIG. 5 of this invention.
- ICOVIR5 does not express E1a by presenting the E2F promoter isolated with MD.
- the level of expression of E1a is higher in ICOVIR5 than in ICOVIR2, which demonstrates the effect of the Kozak sequence to increase the potency of the promoter isolated with MD.
- the Kozak Sequence Enables an Increase in the Oncolytic Potency of an Adenovirus in which the Expression of E1a is Regulated with the E2F1 Promoter Isolated with the MD Sequence
- An oncolytic adenovirus was constructed with E1a regulated with an E2F1 promoter modified by the insertion of four sites for bonding to E2F.
- E1a regulated with an E2F1 promoter modified by the insertion of four sites for bonding to E2F.
- pGEM-E2FKE1ad24 described in example 2
- BsiWI linked two copies of oligonucleotides with the palindromic sequence of bonding to E2F and that had extremes compatible with BsiWI.
- the promoter thus modified was subcloned in Kpn1 of pShuttle-MD-E2F-D24 to obtain pShMDE2FBsiE2F2KE1ad24.
- the plasmid pICOVIR7 was obtained.
- the virus ICOVIR7 was generated by digestion in the A549 line and purified by methods described in gene therapy and virotherapy 36 . Its structure is presented in FIG. 1 of this invention.
- the correct sequence of the promoter and E1a was checked by restriction and sequencing. The sequence obtained is shown in SEQ. ID 3.
- E1a in the tumor line 1.36.1.5 of melanoma by western blot as described in example 1.
- the oncolytic adenovirus ICOVIR7 is distinguished from ICOVIR5 by having the modified E2F1 promoter.
- the results are shown in FIG. 7 of this invention.
- the level of expression of E1a is greater in ICOVIR7, which demonstrates the potentiating role of the two additional sites for bonding to E2F in ICOVIR7.
- the addition of E1a is greater in ICOVIR5 than in ICOVIR2, which demonstrates once again the effect of the Kozak sequence in increasing the potency of the promoter isolated with MD.
- FIG. 8 shows the tumor volume compared with the start of treatment (day 0). The results are presented as a mean ⁇ SD. The existence of significant differences between results was calculated using a Mann-Whitney non-parametric study of data not paired. The growth curves were compared using a variance analysis. The results were considered significant if p ⁇ 0.05. The calculations were made with the statistics package SPSS(SPSS Inc., Chicago, Ill.). There is a significant difference between tumor size on days 16 and 21.
- ICOVIR5 Tumors of the cell line of human melanoma SKMel-28 (1.10 7 cells/tumor) were planted in Balb C nu/nu athymic rats, and once established, were treated by administration in the tail vein with PBS, with a single injection on day 0 of ICOVIR-5 of 2.5.10 10 viral particles (vp), or 1.10 11 vp, or with an injection of 3.10 10 vp and another of 1.10 11 one hour apart. The results are shown in the lower part of FIG. 8 of this invention. All regimes of treatment with ICOVIR-5 showed oncolytic activity that results in a suppression of tumor growth that is significantly different from the control group (PBS), p ⁇ 0.05.
- PBS control group
- the toxicity in vivo of an adenovirus that contains the Kozak sequence in E1a and an E2F1 promoter isolated by MD was compared with that of a salvage virus and the oncolytic virus AdD24RGD that expresses E1a below the salvage promoter.
- the viruses were administered intravenously at different doses and at 5 days post-injection, we assessed parameters related to toxicity, such as animal survival, body weight, level of serum transaminases, and blood count. The results are shown in FIG. 9 of this invention.
- the lethal-dose 50 value (LD 50 ) for AdwtRGD or Ad ⁇ 24RGD in immunocompetent Balb/C rats is located in 5.10 10 viral particles (vp)/rat on day 5 post-injection, while the double of this dose (1.10 11 vp/rat) is lethal for only 10% of rats (LD 10 ) injected with ICOVIR-5.
- the rats injected with 5.10 10 vp of AdwtRGD or Ad ⁇ 24RGD on day 5 post-injection experienced significant weight loss, while the weight of the rats injected with ICOVIR-5 increased.
- the analysis of the expression of the adenoviral protein E1A in the rats' livers by immunodetection in frozen sections obtained on day 5 post-injection shows that the presence of an isolated version of the E2F-1 promoter in ICOVIR-5 is effective in restricting the expression of viral proteins, even when the dose administered is increased ( FIG. 10 ).
- the histological assessment by staining with hematoxylin/eosin of sections in paraffin of the livers on day 3 post-injection also confirmed the low toxicity of ICOVIR-5 ( FIG. 10 ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/327,840 US20150071881A1 (en) | 2006-02-01 | 2014-07-10 | Oncolytic Adenoviruses for Cancer Treatment |
US15/144,637 US10016470B2 (en) | 2006-02-01 | 2016-05-02 | Oncolytic adenoviruses for cancer treatment |
US16/028,037 US20190183946A1 (en) | 2006-02-01 | 2018-07-05 | Oncolytic adenoviruses for cancer treatment |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200600216 | 2006-01-02 | ||
ES200600216A ES2304281B1 (es) | 2006-02-01 | 2006-02-01 | Adenovirus oncoliticos para el tratamiento del cancer. |
PCT/ES2007/000050 WO2007088229A1 (es) | 2006-02-01 | 2007-01-31 | Adenovirus oncolíticos para el tratamiento del cáncer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2007/000050 Continuation WO2007088229A1 (es) | 2006-01-02 | 2007-01-31 | Adenovirus oncolíticos para el tratamiento del cáncer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/327,840 Continuation US20150071881A1 (en) | 2006-02-01 | 2014-07-10 | Oncolytic Adenoviruses for Cancer Treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090311219A1 true US20090311219A1 (en) | 2009-12-17 |
Family
ID=38327139
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/184,881 Abandoned US20090311219A1 (en) | 2006-01-02 | 2008-08-01 | Oncolytic Adenoviruses for Cancer Treatment |
US14/327,840 Abandoned US20150071881A1 (en) | 2006-02-01 | 2014-07-10 | Oncolytic Adenoviruses for Cancer Treatment |
US15/144,637 Expired - Fee Related US10016470B2 (en) | 2006-02-01 | 2016-05-02 | Oncolytic adenoviruses for cancer treatment |
US16/028,037 Abandoned US20190183946A1 (en) | 2006-02-01 | 2018-07-05 | Oncolytic adenoviruses for cancer treatment |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/327,840 Abandoned US20150071881A1 (en) | 2006-02-01 | 2014-07-10 | Oncolytic Adenoviruses for Cancer Treatment |
US15/144,637 Expired - Fee Related US10016470B2 (en) | 2006-02-01 | 2016-05-02 | Oncolytic adenoviruses for cancer treatment |
US16/028,037 Abandoned US20190183946A1 (en) | 2006-02-01 | 2018-07-05 | Oncolytic adenoviruses for cancer treatment |
Country Status (8)
Country | Link |
---|---|
US (4) | US20090311219A1 (de) |
EP (1) | EP1990418B1 (de) |
JP (1) | JP5075839B2 (de) |
CN (1) | CN101484583A (de) |
AU (1) | AU2007211434A1 (de) |
CA (1) | CA2640528C (de) |
ES (1) | ES2304281B1 (de) |
WO (1) | WO2007088229A1 (de) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140227226A1 (en) * | 1999-05-12 | 2014-08-14 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
US20150374766A1 (en) * | 2013-03-14 | 2015-12-31 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
US10849945B2 (en) | 2015-04-30 | 2020-12-01 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein or active fragment |
US11130968B2 (en) | 2016-02-23 | 2021-09-28 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
US11155622B2 (en) | 2015-12-17 | 2021-10-26 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
US11401529B2 (en) | 2016-02-23 | 2022-08-02 | Salk Institute For Biological Studies | Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics |
US11439678B2 (en) | 2013-10-25 | 2022-09-13 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
US11813337B2 (en) | 2016-12-12 | 2023-11-14 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
US11840702B2 (en) | 2017-08-28 | 2023-12-12 | Akamis Bio Limited | Adenovirus armed with bispecific T cell activator |
US12049513B2 (en) | 2016-08-29 | 2024-07-30 | Akamis Bio Limited | Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
US8138318B2 (en) * | 2007-09-13 | 2012-03-20 | Abbott Laboratories | Hepatitis B pre-S2 nucleic acid |
WO2010097419A1 (en) | 2009-02-25 | 2010-09-02 | Fundació Privada Centre De Regulació Genòmica (Crg) | Conditionally replicating adenovirus effective in the treatment of tumors |
ES2355882B1 (es) * | 2009-03-24 | 2012-02-13 | INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) | Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer. |
FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
KR20160137946A (ko) * | 2013-11-22 | 2016-12-02 | 디엔에이트릭스, 인코포레이티드 | 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스 |
WO2017065497A1 (ko) * | 2015-10-12 | 2017-04-20 | 한양대학교 산학협력단 | 유전자 전달 및 유전자 치료를 위한 아데노바이러스 복합체 |
DK3293201T3 (da) * | 2016-09-12 | 2020-12-07 | Targovax Oy | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer |
WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
CN110684743A (zh) * | 2019-07-16 | 2020-01-14 | 伍泽堂 | 特异性杀伤肿瘤细胞的病毒和肿瘤治疗药物 |
BR112022001912A2 (pt) | 2019-08-05 | 2022-04-19 | Mesoblast Int Sarl | Composições celulares compreendendo vetores virais e métodos de tratamento |
JP2023537103A (ja) | 2020-08-10 | 2023-08-30 | メゾブラスト・インターナショナル・エスアーエールエル | 細胞組成物及び治療方法 |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936450B2 (en) * | 2000-04-12 | 2005-08-30 | Compugen Ltd. | Variants of protein kinases |
US20060147420A1 (en) * | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
US20060188990A1 (en) * | 2002-04-19 | 2006-08-24 | Schering Aktiengesellschaft | Novel prostate tumor-specific promoter |
US20070292396A1 (en) * | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
US20090312401A1 (en) * | 2006-04-28 | 2009-12-17 | Osvaldo Luis Podhajcer | Isolated dna fragment of the sparc human promoter and its use for driving the expression of an heterologous gene in tumor cells |
US20100113569A1 (en) * | 2006-04-28 | 2010-05-06 | Inis Biotech Llc | Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049868A1 (en) * | 1999-12-31 | 2001-07-12 | Korea Research Institute Of Bioscience And Biotechnology | Cancer cell-specific gene expression system |
JP2004536572A (ja) * | 2001-02-23 | 2004-12-09 | セル・ジェネシス・インコーポレイテッド | 新規ベクター構築物 |
WO2003070958A1 (en) * | 2002-02-19 | 2003-08-28 | The Hospital For Sick Children | Retroviral gene therapy vectors including insulator elements to provide high levels of gene expression |
ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
-
2006
- 2006-02-01 ES ES200600216A patent/ES2304281B1/es not_active Expired - Fee Related
-
2007
- 2007-01-31 JP JP2008552833A patent/JP5075839B2/ja not_active Expired - Fee Related
- 2007-01-31 EP EP07704759A patent/EP1990418B1/de not_active Not-in-force
- 2007-01-31 AU AU2007211434A patent/AU2007211434A1/en not_active Abandoned
- 2007-01-31 CA CA2640528A patent/CA2640528C/en not_active Expired - Fee Related
- 2007-01-31 WO PCT/ES2007/000050 patent/WO2007088229A1/es active Search and Examination
- 2007-01-31 CN CNA2007800091899A patent/CN101484583A/zh active Pending
-
2008
- 2008-08-01 US US12/184,881 patent/US20090311219A1/en not_active Abandoned
-
2014
- 2014-07-10 US US14/327,840 patent/US20150071881A1/en not_active Abandoned
-
2016
- 2016-05-02 US US15/144,637 patent/US10016470B2/en not_active Expired - Fee Related
-
2018
- 2018-07-05 US US16/028,037 patent/US20190183946A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936450B2 (en) * | 2000-04-12 | 2005-08-30 | Compugen Ltd. | Variants of protein kinases |
US20060188990A1 (en) * | 2002-04-19 | 2006-08-24 | Schering Aktiengesellschaft | Novel prostate tumor-specific promoter |
US20060147420A1 (en) * | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
US20070292396A1 (en) * | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
US20090312401A1 (en) * | 2006-04-28 | 2009-12-17 | Osvaldo Luis Podhajcer | Isolated dna fragment of the sparc human promoter and its use for driving the expression of an heterologous gene in tumor cells |
US20100113569A1 (en) * | 2006-04-28 | 2010-05-06 | Inis Biotech Llc | Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells |
Non-Patent Citations (1)
Title |
---|
Duque et al, Direct Comparison of the Insulating Properties of Two Genetic Elements in an Adenoviral Vector Containing Two Different Expression Cassettes, HUMAN GENE THERAPY 15:995-1002 (October 2004) * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10391183B2 (en) * | 1999-05-12 | 2019-08-27 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
US20140227226A1 (en) * | 1999-05-12 | 2014-08-14 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
US20150374766A1 (en) * | 2013-03-14 | 2015-12-31 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
US11077156B2 (en) * | 2013-03-14 | 2021-08-03 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
US11439678B2 (en) | 2013-10-25 | 2022-09-13 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
US11938159B2 (en) | 2013-10-25 | 2024-03-26 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
US10849945B2 (en) | 2015-04-30 | 2020-12-01 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein or active fragment |
US11000559B2 (en) | 2015-04-30 | 2021-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein |
US11155622B2 (en) | 2015-12-17 | 2021-10-26 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
US11970536B2 (en) | 2015-12-17 | 2024-04-30 | Akamis Bio Limited | Group B adenovirus encoding an anti-TCR-complex antibody or fragment |
US11401529B2 (en) | 2016-02-23 | 2022-08-02 | Salk Institute For Biological Studies | Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics |
US11130968B2 (en) | 2016-02-23 | 2021-09-28 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
US12049513B2 (en) | 2016-08-29 | 2024-07-30 | Akamis Bio Limited | Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager |
US11813337B2 (en) | 2016-12-12 | 2023-11-14 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
US11840702B2 (en) | 2017-08-28 | 2023-12-12 | Akamis Bio Limited | Adenovirus armed with bispecific T cell activator |
Also Published As
Publication number | Publication date |
---|---|
ES2304281B1 (es) | 2009-08-12 |
EP1990418B1 (de) | 2012-08-29 |
US20150071881A1 (en) | 2015-03-12 |
WO2007088229A1 (es) | 2007-08-09 |
US20190183946A1 (en) | 2019-06-20 |
AU2007211434A1 (en) | 2007-08-09 |
US10016470B2 (en) | 2018-07-10 |
EP1990418A1 (de) | 2008-11-12 |
EP1990418A4 (de) | 2011-02-23 |
ES2304281A1 (es) | 2008-10-01 |
CN101484583A (zh) | 2009-07-15 |
CA2640528A1 (en) | 2007-08-09 |
JP5075839B2 (ja) | 2012-11-21 |
US20160354420A1 (en) | 2016-12-08 |
JP2009525036A (ja) | 2009-07-09 |
CA2640528C (en) | 2015-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10016470B2 (en) | Oncolytic adenoviruses for cancer treatment | |
EP1180932B1 (de) | Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen | |
US10391183B2 (en) | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof | |
JP5746823B2 (ja) | E3−19kタンパク質の小胞体保持ドメインに突然変異を有するアデノウイルス及び癌治療におけるその用途 | |
Wu et al. | Cancer gene therapy by adenovirus-mediated gene transfer | |
US20050036989A1 (en) | Subgroup B adenoviral vectors for treating disease | |
US9175309B2 (en) | Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus | |
RU2814581C1 (ru) | Генетический вектор Ad6/3-hTERT-GMCSF, содержащий геномные последовательности рекомбинантного аденовируса 6 серотипа, промотор теломеразы человека, ген гранулоцитарно-макрофагального колониестимулирующего фактора человека, а также ген белка файбер со встройкой домена fiber knob аденовируса 3 серотипа, обладающий повышенной трансдукцией в опухолевые клетки | |
CA2627638A1 (en) | Conditionally replicating viruses and methods for cancer virotherapy | |
Alemany | Conditionally replicating adenoviruses for cancer treatment | |
Coughlan | Transductional retargeting of human adenovirus type 5 to ανβ6 integrin for cancer gene therapy | |
Särkioja | Adenoviral gene therapy for non-small cell lung cancer | |
Tanaka et al. | Recent developments in cancer gene therapy with adenovirus vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DNATRIX, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSTITUT CATALA D'ONCOLOGIA;REEL/FRAME:022803/0798 Effective date: 20070301 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |